Cure Pharmaceutical announced today that it observed positive results from a trial for its Curefilm Blue platform.
Oxnard, Calif.-based Cure touted the results of its initial pharmacokinetics (PK)/bioequivalence studies ahead of the advancement of its clinical program in pursuit of FDA approval, according to a news release. The company did not reveal the specific data, but said the results are positive and will help it move forward development of the Curefilm Blue platform.
Curefilm Blue is based on Cure’s proprietary Curefilm fast-dissolving drug delivery platform. It delivers the active pharmaceutical ingredient sildenafil citrate to move drug delivery beyond traditional pills and solutions while also aiming to enhance the patient experience.
“These results further validate CURE’s oral soluble film dosage form, establishing our drug delivery technology platform, and offering patients a better experience and an opportunity to avoid the need to swallow a pill,” Cure CSO Dr. Vered Gigi said in the release.
“As the first of many of CURE’s specialty pharmaceutical programs, we are excited by this outcome. We are now accelerating our partnering initiatives with an eye toward future commercialization,” added chief business officer Jonathan Berlent.
